Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
Natera (NASDAQ: NTRA) has secured a new patent (No. 12,203,142) from the U.S. Patent and Trademark Office, strengthening its intellectual property portfolio in tumor-informed molecular residual disease (MRD) testing. The patent specifically covers methods for testing single nucleotide variants in circulating-tumor DNA (ctDNA) using whole exome and whole genome sequencing.
The patent details various target enrichment techniques in plasma, including multiplex polymerase chain reaction PCR and capture by hybridization. This addition expands Natera's extensive intellectual property estate, which now includes over 110 patents in cell-free DNA analysis for oncology testing, with 23 patents obtained in 2024 alone.
Natera (NASDAQ: NTRA) ha ottenuto un nuovo brevetto (No. 12,203,142) presso l'Ufficio Brevetti e Marchi degli Stati Uniti, rafforzando il suo portafoglio di proprietà intellettuale nel test della malattia residua molecolare informata dal tumore (MRD). Il brevetto copre specificamente i metodi per testare le varianti a singolo nucleotide nel DNA tumorale circolante (ctDNA) utilizzando il sequenziamento dell'intero esoma e dell'intero genoma.
Il brevetto descrive varie tecniche di arricchimento dei target nel plasma, inclusa la PCR multiplex e la cattura per ibridazione. Questa aggiunta amplia l'ampio patrimonio di proprietà intellettuale di Natera, che ora include oltre 110 brevetti nell'analisi del DNA libero per test oncologici, con 23 brevetti ottenuti nel solo 2024.
Natera (NASDAQ: NTRA) ha asegurado una nueva patente (No. 12,203,142) de la Oficina de Patentes y Marcas de EE. UU., fortaleciendo su cartera de propiedad intelectual en pruebas de enfermedad residual molecular informada por tumores (MRD). La patente cubre específicamente métodos para probar variantes de nucleótido único en ADN tumoral circulante (ctDNA) utilizando secuenciación de exoma completo y genoma completo.
La patente detalla varias técnicas de enriquecimiento de objetivos en plasma, incluyendo la reacción en cadena de la polimerasa multiplex (PCR) y la captura por hibridación. Esta adición expande la extensa cartera de propiedad intelectual de Natera, que ahora incluye más de 110 patentes en el análisis de ADN libre para pruebas oncológicas, con 23 patentes obtenidas solo en 2024.
네이테라 (NASDAQ: NTRA)는 미국 특허청으로부터 새로운 특허(번호 12,203,142)를 확보하여 종양 정보에 기반한 분자 잔여 질병(MRD) 검사에서 지적 재산 포트폴리오를 강화했습니다. 이 특허는 전체 엑솜 및 전체 게놈 시퀀싱을 사용하여 순환 종양 DNA(ctDNA)에서 단일 뉴클레오타이드 변이를 테스트하는 방법을 구체적으로 다룹니다.
특허는 플라즈마에서의 다양한 타겟 농축 기술을 설명하고 있으며, 여기에는 다중 중합효소 연쇄 반응(PCR) 및 하이브리다이제이션에 의한 캡처가 포함됩니다. 이 추가 사항은 Natera의 방대한 지적 재산권을 확장하며, 현재 종양학 검사를 위한 세포 자유 DNA 분석에 대해 110개 이상의 특허를 포함하고 있으며, 2024년에는 단독으로 23개의 특허를 획득했습니다.
Natera (NASDAQ: NTRA) a obtenu un nouveau brevet (No. 12,203,142) de l'Office des brevets et des marques des États-Unis, renforçant son portefeuille de propriété intellectuelle dans les tests de maladie résiduelle moléculaire informée par les tumeurs (MRD). Le brevet couvre spécifiquement des méthodes pour tester des variantes de nucléotides uniques dans l'ADN tumoral circulant (ctDNA) en utilisant le séquençage de l'exome entier et du génome entier.
Le brevet détaille diverses techniques d'enrichissement des cibles dans le plasma, y compris la réaction de polymérase en chaîne multiplex (PCR) et la capture par hybridation. Cet ajout élargit le vaste portefeuille de propriété intellectuelle de Natera, qui comprend désormais plus de 110 brevets dans l'analyse de l'ADN libre pour les tests oncologiques, avec 23 brevets obtenus rien que pour 2024.
Natera (NASDAQ: NTRA) hat ein neues Patent (Nr. 12,203,142) vom US-Patent- und Markenamt erhalten, wodurch ihr Portfolio an geistigem Eigentum im Bereich der tumorinformierten molekularen Restkrankheit (MRD) Tests gestärkt wird. Das Patent deckt speziell Methoden zur Testung von einzelnen Nukleotidvarianten in zirkulierender Tumor-DNA (ctDNA) mittels Ganzexom- und Gesamtegenom-Sequenzierung ab.
Das Patent beschreibt verschiedene Zielanreicherungstechniken im Plasma, einschließlich multiplexer Polymerase-Kettenreaktion (PCR) und Hybridisierung. Diese Ergänzung erweitert Nateras umfangreiches geistiges Eigentum, das nun über 110 Patente in der Analyse von zellfreiem DNA für onkologische Tests umfasst, wobei allein im Jahr 2024 23 Patente erlangt wurden.
- Secured new strategic patent for tumor-informed MRD testing
- Expanded IP portfolio to 110+ patents in cell-free DNA analysis
- Obtained 23 new patents in 2024
- None.
Natera has more than 110 patents relating to cell-free DNA analysis for oncology testing, including 23 patents obtained in 2024.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to the scope of protection we establish and maintain for our intellectual property or other proprietary rights. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250303806272/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
Source: Natera, Inc.
FAQ
What is the significance of Natera's new patent No. 12,203,142?
How many patents does Natera (NTRA) currently hold for cell-free DNA analysis?
How many new patents has NTRA secured in 2024?
What specific technologies are covered in Natera's latest patent?
